PartnershipJun 2, 2026, 07:01 AM
Telix Pharma, United Imaging Partner for Integrated Theranostics
AI Summary
Telix Pharmaceuticals and United Imaging Healthcare North America have signed a Memorandum of Understanding to establish a strategic research collaboration in the U.S. The partnership aims to advance integrated theranostics solutions by combining United Imaging's advanced scanner platforms and AI capabilities with Telix's molecular imaging portfolio. The initial focus will be on Telix's TLX101-Px (Pixclara®), a PET imaging candidate with an FDA PDUFA goal date of September 11, 2026, for recurrent or progressive glioma. This collaboration seeks to enhance workflow efficiencies, standardize imaging performance, and support data-driven clinical decision-making.
Key Highlights
- Telix Pharmaceuticals and United Imaging signed an MoU for strategic research collaboration.
- Partnership focuses on advancing integrated theranostics solutions in the U.S.
- Initial collaboration targets Telix's TLX101-Px (Pixclara®) in the U.S.
- TLX101-Px NDA accepted by FDA in April 2026.
- FDA PDUFA goal date for TLX101-Px is September 11, 2026.
- Collaboration aims to integrate imaging systems, radiopharmaceutical workflows, and AI.
- Supports treatment planning, monitoring, and patient management.
Price Impact
More from TLX